Perspective · 30 Aug 2022
Conference abstract
Myelofibrosis management updates
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Myeloproliferative neoplasms (MPN) are myeloid hematologic neoplasms that are characterized by expansion of terminal myeloid cells (white blood cells, platelet, red blood cells) and their precursors in the bone marrow (BM) and peripheral blood. MPN include primary myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia and a few other less common neoplasm. The term myelofibrosis (MF) combines primary myelofibrosis and myelofibrotic transformation of other myeloproliferative neoplasms, namely essential thrombocythemia and polycythemia vera, due to the similar disease characteristics and clinical outcomes. MF is manifested by increased interstitial collagen deposits in the BM, extramedullary hematopoiesis which can result in massive enlargement of the spleen, abnormal blood counts, and debilitating symptoms (e.g., fatigue, weakness, abdominal pain, cachexia, weight loss, pruritus, night sweats, and bone pain) which are thought to be caused by the combined effects of massive splenomegaly and elevated levels of pro-inflammatory cytokines. Survival of patients with MF is compromised and ranges from 2 to 11 years depending on defined prognostic factors. The majority of patients suffer a heavy burden of symptoms due to their disease and/or their low blood counts. Traditional therapeutic options are only palliative and include splenectomy, chemotherapy, immunomodulatory drugs and targeted therapies such as Jak-2 inhibitors. Only allogeneic hematopoietic stem cell transplantation can favorably impact the natural disease course of MF but, unfortunately, few patients are eligible for this treatment.The scarcity of therapeutic options is partially attributable to our limited understanding of the key processes driving this malignancy. There have been several advances in the understanding of the disease biology and the available therapeutic interventions.
Subjects
HaematologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 29 May 2017
An Update: Standardized Hypertension Management to Reduce Cardiovascular Disease Morbidity and Mortality Worldwide
Conference abstract · 18 Aug 2016
The management of traumatic intracranial hemorrhage in patients taking pre-injury antiplatelet agents: An update
Conference abstract
Review and update in the management of Myelodysplastic Syndrome (MDS)
Brief report · 29 Nov 2025
Alzheimer’s: Therapies, Diagnostics, Genetics, Management Update
More from this journal
The newest in Journal of Blood Disorders & Transfusion.
Article · 8 Jun 2026
Analysis of Motivations and Barriers to Voluntary Blood Donation in the Thessalian Population: Findings from a Quantitative Study
Article · 30 Apr 2026
Cellular Neighbourhoods of Blood Formation: Understanding the Hematopoietic Microenvironment
Article · 30 Apr 2026
Erythrocyte Membrane Disorders: Structural Defects and Their Impact on Red Blood Cell Survival
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Blood Disorders & Transfusion
- SubjectHaematology
- BylineArticles whose byline prints “Abdulraheem Yacoub”
